207940 — Samsung Biologics Co Balance Sheet
0.000.00%
Last trade - 00:00- KR₩72tn
- KR₩71tn
- KR₩5tn
Annual balance sheet for Samsung Biologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,347,450 | 3,171,705 | 2,022,450 | 1,298,572 | 1,456,026 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 430,242 | 820,156 | 742,712 | 1,246,732 | 780,094 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,823,175 | 6,457,657 | 5,521,988 | 5,518,118 | 4,408,367 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,227,687 | 3,871,452 | 4,342,424 | 5,837,482 | 6,037,532 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 7,970,011 | 16,582,050 | 16,046,197 | 17,336,296 | 11,060,742 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,107,295 | 4,181,542 | 4,157,861 | 3,853,188 | 2,532,917 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,978,909 | 7,597,576 | 6,215,705 | 6,431,620 | 3,609,631 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 4,991,102 | 8,984,474 | 9,830,492 | 10,904,676 | 7,451,111 |
| Total Liabilities & Shareholders' Equity | 7,970,011 | 16,582,050 | 16,046,197 | 17,336,296 | 11,060,742 |
| Total Common Shares Outstanding |